Key facts
- This page summarizes NEW ENTERPRISE ASSOCIATES 13 LP's Form 4 filing for PhaseBio Pharmaceuticals Inc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2022, 16:41.
NEW ENTERPRISE ASSOCIATES 13 LP - 25 Oct 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 25 Oct 2022
- Net transaction value
- -$262,264
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2022, 16:41:37 UTC
- Prior SEC filing
- 07 Dec 2021
- Next SEC filing
- 10 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Louis Citron, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
NEW ENTERPRISE ASSOCIATES 13 LP filed Form 4 for PhaseBio Pharmaceuticals Inc on 26 Oct 2022.
Change
- Previous filing in this sequence was filed on 07 Dec 2021.
- Current net transaction value: -$262,264.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHASQ
transaction
Common Stock
Sale
- Transaction value
- $262,264
- Shares
- -1,784,109
- Change %
- -27%
- Price
- $0.1470*
- Shares after
- 4,857,525
- Date
- 25 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
NEW ENTERPRISE ASSOCIATES 13 LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.13 to $0.1548, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
Footnote F2
The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 13 in which the Indirect Reporting Persons have no pecuniary interest.